Advanced Accelerator Preps Lutetium-Tipped Warhead For NETs Filing
This article was originally published in Scrip
Executive Summary
You may also be interested in...
Confirming Rumors, Novartis Buys AAA To Boost Oncology Business
Integrating AAA will add to Novartis' expertise in diseases associated with neuroendocrine tumors and bring it a new technology platform for treating cancer.
Novartis Confirms Rumors With $3.9bn Deal For AAA's Nuclear Med Biz
Recent speculation about Novartis' interest in nuclear medicine specialist AAA has been confirmed, after the pharma giant inked a deal worth $3.9bn to acquire the French firm. Integrating AAA would add to Novartis' expertise in diseases associated with neuroendocrine tumors and bring it a new technology platform for treating cancer.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.